Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Targeting the tumor mutanome for personalized vaccination in lung cancer

ABSTRACT: Targeting the tumor mutanome for personalized vaccination in lung cancer

PROVIDER: PRJNA745456 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR15097633_1.fastq.gz	Fastqsanger.gz
	SRR15097633_2.fastq.gz	Fastqsanger.gz
	SRR15097634_1.fastq.gz	Fastqsanger.gz
	SRR15097634_2.fastq.gz	Fastqsanger.gz
	SRR15097635_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 40

Similar Datasets

Targeting the tumor mutanome for personalized vaccination in lung cancer

Project description:Cancer is characterized by an accumulation of somatic mutations, of which a significant subset can generate cancer-specific neoepitopes that are recognized by autologous T cells. Neoepitopes are emerging as important targets for cancer immunotherapy, including personalized cancer vaccination strategies. We used whole-exome and RNA sequencing analysis to identify potential neoantigens for a patient with non-small cell lung cancer. Sequencing revealed a low tumor mutational burden: 2,219 sequence variants were identified from the primary tumor, of which 23 were expressed in the transcriptome, involving 18 gene products. We assessed autologous T-cell reactivity to the candidate neoantigens using a long peptide approach and could demonstrate spontaneous T-cell responses to 5/18 (28%) mutated gene variants. Further, analysis of the TCR repertoire of neoantigen-specific CD4+ and CD8+ T cells revealed TCR clonotypes that were expanded in both blood and tumor tissue. In parallel, the 18 gene variants were incorporated into a Modified Vaccinia Ankara-based vaccine, which was evaluated in the transgenic HLA-A*02-restricted HHD mouse model. Following vaccination, de novo T-cell responses were generated to 4/18 (22%) mutated gene variants, of which 2 were also observed in the autologous setting; we determined the MHC restriction of the T-cell responses and used in silico prediction tools to determine the likely neoepitopes. Our study demonstrates the feasibility of efficiently identifying tumor-specific neoantigens that can be targeted by vaccination in tumors with a low mutational burden, and promises successful clinical application, with trials currently underway.

2022-04-27 | GSE179879 | GEO

The HLA-ligandome of oropharyngeal squamous cell carcinomas reveals shared tumor-exclusive peptides for semi-personalized vaccination

Project description:Oropharyngeal squamous cell carcinoma (OPSCC) is diagnosed in 93,000 patients worldwide per year and 51,000 annual deaths can be attributed to this disease. OPSCCs are either human papillomavirus associated (HPV-positive) cancers or non-virally induced, primarily tobacco and alcohol associated (HPV-negative) cancers. MS analysis enabled the identification of naturally HLA-presented peptides in OPSCC tumor tissue. By comparative profiling against benign HLA ligandomic datasets, we demonstrated that tumor-associated peptides are HLA-presented on the cell surfaces of OPSCCs. The established warehouse of OPSCC-associated peptides can be used for downstream immunogenicity testing and peptide-based immunotherapy in (semi-) personalized strategies.

2023-02-27 | PXD033383 | Pride

Detection of oncoantigens suitable for lung cancer vaccination

2013-12-30 | GSE30878 | GEO

Detection of oncoantigens suitable for lung cancer vaccination

Project description:The lung cancer tumor K-rasLA1/ p53 R172HDeltag mouse model was used to identify genes associated to the tumor mass increase in lungs. Those genes were then ranked on the basis of their oncogenic potential using a metadataset encompassing 695 human lung adenocarcinomas and ranking them on the basis of their expression in normal tissues. The genes characterized by the higher oncogenic potential combined to a low expression in normal tissues were selected as putative targets for preclinical studies on lung cancer vaccination. Two prototypic situations (WT, and MUT) were examined using Exon arrays over a three-points time course (10, 20, and 30 weeks old animals), for each time point two/three male and female animals were used. A total of 30 mouse Exon 1.0 arrays were hybridized.

2013-12-30 | E-GEOD-30878 | biostudies-arrayexpress

Targeting E-Proteins Licenses cDC1 Immunogenicity for Potent Anti-Tumor Vaccination [RNA-seq]

Project description:Targeting E-Proteins Licenses cDC1 Immunogenicity for Potent Anti-Tumor Vaccination [RNA-seq]

| PRJNA1435201 | ENA

Targeting E-Proteins Licenses cDC1 Immunogenicity for Potent Anti-Tumor Vaccination [ChIP-seq]

Project description:Targeting E-Proteins Licenses cDC1 Immunogenicity for Potent Anti-Tumor Vaccination [ChIP-seq]

| PRJNA1435198 | ENA

Adjuvant personalized multivalent neoantigen DNA vaccination for MGMT unmethylated glioblastoma: a phase I trial [scRNA-seq]

Project description:Glioblastoma is a devastating disease with a prognosis of less than 24 months. Recent studies have shown encouraging results using neoantigen-based vaccines to stimulate glioblastoma-directed immune responses, but overall immunogenicity has been low. Here, we report the results of a phase 1 clinical trial (NCT04015700) to assess the safety and efficacy of GNOS-PV01, a personalized DNA vaccine platform, in patients with newly diagnosed MGMT unmethylated glioblastoma following surgery and radiation. Results show GNOS-PV01 is able to safely immunize against up to 40 neoantigens per patient (range 17-40) with neoantigen-specific T cell responses detectable in all evaluated subjects post-vaccination (7 of 7). Furthermore, we developed a novel T cell enrichment method for single nuclei RNA-sequencing to transcriptionally characterize tumor-infiltrating T cells after vaccination. Survival outcomes were encouraging with one-third of vaccinated patients (3 of 9) alive beyond 24 months. Moreover, induction of neoantigen-specific responses was associated with subsequent reactivity to PD-1 blockade therapy.

2026-02-10 | GSE292046 | GEO

Adjuvant personalized multivalent neoantigen DNA vaccination for MGMT unmethylated glioblastoma: a phase I trial [RNA-seq]

2026-02-10 | GSE292045 | GEO

First-in-human clinical trial of personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphoma

Project description:We performed single cell RNA-seq gene expression analysis on bone marrow of 9 lymphoplasmacytic lymphoma patients before and after vaccination with personalized idiotype DNA vaccine to study changes in tumor microenvironment

2023-09-20 | GSE243545 | GEO

The HLA-ligandome of oropharyngeal squamous cell carcinomas reveals shared tumor-exclusive peptides for semi-personalized vaccination

2025-11-18 | MSV000099949 | MassIVE